(Reuters) — AbbVie said on Thursday it will buy ImmunoGen for $10.1 billion, underscoring a growing interest from large drugmakers in a promising class of targeted cancer therapies.

U.S. drugmaker AbbVie said on Monday it will acquire cell therapy developer Capstan Therapeutics in a cash deal worth up to ...

ImmunoGen shares skyrocketed over 80% in early trading Thursday after AbbVie agreed to buy the rival biotech firm for $10.1 billion to expand its cancer drug portfolio.

The time is right to expand AbbVie's business with its $10 billion acquisition of ImmunoGen . ImmunoGen is a commercial-stage oncology company focused on developing antibody-drug conjugates (ADCs ...

AbbVie’s $2.1 billion acquisition of Capstan Therapeutics aims to advance in vivo CAR-T therapies, transforming autoimmune ...

Pharmaceutical giant AbbVie said Thursday it has agreed to pay more than $10 billion to buy Waltham cancer drug maker ImmunoGen, in the largest acquisition of a Massachusetts company this year.

AbbVie Inc. (NYSE:ABBV) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, the “Elahere ...

On Nov. 30, AbbVie announced its plans to acquire ImmunoGen in an all-cash transaction valued at roughly $10.1 billion. This deal stands to become AbbVie's largest acquisition since it purchased ...

This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.

Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...

AbbVie is still carrying over $71 billion in long-term debt from an acquisition spree that included a $63 billion purchase of Allergan, $10.1 billion for ImmunoGen, and $8.7 billion for Cerevel ...

ImmunoGen acquisition. AbbVie completed the $10 billion acquisition of ImmunoGen in February this ... My philosophy on accumulating AbbVie stock has been to buy when the dividend yield exceeds 4%.